Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)

• Published in: Journal of hematology and oncology Vol. 15; no. 1; pp. 1 - 12
• Main Authors: Zhao, Wan-Hong, Wang, Bai-Yan, Chen, Li-Juan, Fu, Wei-Jun, Xu, Jie, Liu, Jie, Jin, Shi-Wei, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Zhang, Hui, Bai, Ju, Xu, Yan, Zhu, Han, Du, Juan, Jiang, Hua, Fan, Xiao-Hu, Li, Jian-Yong, Hou, Jian, Chen, Zhu, Zhang, Wang-Gang, Mi, Jian-Qing, Chen, Sai-Juan, He, Ai-Li
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 06.07.2022; BioMed Central; BMC
• Subjects: Antibodies; Antigens; B cell maturation antigen; Cancer therapies; Central nervous system; Chemotherapy; Chimeric antigen receptor therapy; Chimeric antigen receptors; Cyclophosphamide; Cytokines; Diseases; Drug dosages; Drug resistance; Efficacy; Fludarabine; Hematology; Hepatitis B; Infections; Lung cancer; Lymphocytes; Lymphocytes T; Multiple myeloma; Oncology; Patients; Relapse; Safety; Stem cell transplantation; Toxicity; Virus diseases; China

Background LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we repo...